Table 1.
Characteristics of participants in the UK Biobank.
| Characteristics | All | Females | Males | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FMI | TFMI | FMI | TFMI | FMI | TFMI | |||||||
| Q1 | Q5 | Q1 | Q5 | Q1 | Q5 | Q1 | Q5 | Q1 | Q5 | Q1 | Q5 | |
| Age at enrollment (yrs; Median (IQR)) | 53 (46–60) | 60 (53–64) | 53 (46–60) | 60 (53–64) | 53 (46–60) | 59 (53–64) | 53 (46–60) | 59 (52–64) | 54 (47–61) | 61 (53–65) | 54 (46–61) | 61 (55–65) |
| Socioeconomic status (lowest quintile; %) | 17.1 | 18.4 | 17.1 | 18.6 | 17.7 | 19.3 | 17.7 | 19.5 | 15.9 | 16.7 | 15.9 | 17.0 |
| Family history of breast cancer (%) | – | – | – | – | 10.4 | 11.2 | 10.9 | 11.5 | – | – | – | – |
| Age at menarche (<12 yrs.; %) | – | – | – | – | 13.2 | 14.5 | 13.9 | 13.8 | – | – | – | – |
| Nulliparous: (%) | – | – | – | – | 24.6 | 18.1 | 23.6 | 19.2 | – | – | – | – |
| Age at menopause (>55 yrs.; %) | – | – | – | – | 10.4 | 12.9 | 10.6 | 12.6 | – | – | – | – |
| HRT use ever: (never; %) | – | – | – | – | 64.0 | 54.6 | 63.9 | 55.1 | – | – | – | – |
| Mammogram ever (%) | – | – | – | – | 94.0 | 96.1 | 93.5 | 95.7 | – | – | – | – |
| Alcohol ((≥5 times/week; %) | 22.3 | 22.4 | 21.9 | 22.7 | 20.8 | 19.0 | 20.4 | 19.2 | 24.9 | 28.7 | 24.7 | 29.4 |
| Physical activity (MET-min/week; Median (IQR)) | 37.8 (19.1–71.1) | 28.4 (13.6–55.8) | 38.6 (19.4–72.4) | 27.8 (13.5–54.4) | 37.0 (18.5–67.9) | 28.2 (13.6–55.1) | 37.1 (18.5–69.1) | 28.0 (13.6–54.2) | 39.6 (19.9–76.9) | 28.8 (13.6–57.4) | 41.2–21.0–80.5) | 27.6 (12.9–54.7) |
| BMI (kg/m2; Median (IQR)) | 21.1 (20.2–22.1) | 23.9 (23.6–24.7) | 21.3 (20.2–22.4) | 24.2 (23.7–24.6) | 20.7 (19.9–21.6) | 24.3 (23.9–24.7) | 20.9 (19.9–21.9) | 24.2 (23.6–24.6) | 22.0 (20.9–23.0) | 24.3 (23.8–24.7) | 22.1 (20.9–23.2) | 24.3 (23.7–24.7) |
| WC (cm.; Median (IQR)) | 72 (68–79) | 83 (78–89) | 72 (68–79) | 83 (78–89) | 69 (66–72) | 80 (76–83) | 69 (67–73) | 80 (76–83) | 81 (77–85) | 90 (86–94) | 81 (77–85) | 90 (87–94) |
| WHR (median (IQR)) | 0.79 (0.74–0.84) | 0.84 (0.78–0.90) | 0.79 (0.74–0.84) | 0.84 (0.78–0.90) | 0.76 (0.73–0.79) | 0.80 (0.76–0.84) | 0.76 (0.73–0.79) | 0.80 (0.76–0.88) | 0.85 (0.82–0.89) | 0.92 (0.88–0.95) | 0.85 (0.82–0.89) | 0.92 (0.89–0.95) |
| Smoking (never; %) | 60.8 | 56.5 | 60.4 | 56.6 | 62.6 | 59.9 | 62.5 | 60.1 | 57.4 | 50.1 | 56.5 | 49.9 |
| Diabetes (%) | 1.6 | 2.6 | 1.7 | 2.6 | 1.3 | 1.4 | 1.4 | 1.4 | 2.3 | 4.8 | 2.3 | 5.0 |
| Aspirin use ever (%) | 6.6 | 10.9 | 6.6 | 10.9 | 5.2 | 7.8 | 5.3 | 7.4 | 9.2 | 16.7 | 9.2 | 17.5 |
| Ibuprofen use ever (%) | 11.1 | 11.1 | 11.3 | 10.9 | 12.5 | 12.8 | 12.7 | 12.7 | 8.5 | 7.9 | 8.6 | 7.6 |
| Vitamin D use (%) | 5.3 | 4.9 | 5.3 | 4.9 | 6.6 | 5.8 | 6.5 | 5.7 | 3.1 | 3.2 | 3.1 | 3.4 |
| Folate use ever (%) | 2.5 | 2.4 | 2.5 | 2.5 | 3.0 | 2.7 | 3.0 | 2.9 | 1.6 | 1.7 | 1.5 | 1.8 |
| Fruits and vegetable intake (≥5 servings/dy; %) | 28.5 | 25.6 | 28.8 | 25.7 | 31.4 | 28.9 | 31.6 | 29.1 | 23.1 | 19.5 | 23.5 | 19.2 |
| Red meat (≥5 servings/dy; %) | 3.8 | 4.3 | 3.8 | 4.1 | 3.0 | 3.5 | 3.1 | 3.3 | 5.2 | 5.9 | 5.2 | 5.6 |
| Processed meat (≥5 servings/dy; %) | 3.7 | 3.0 | 3.7 | 3.0 | 1.7 | 1.6 | 1.7 | 1.6 | 7.3 | 5.7 | 7.4 | 5.6 |
Number missing: ethnicity (n = 623); smoking status (n = 558); age at menarche (n = 3099); parity and age at first live birth combined (n = 13,265); age at menopause (n = 7515); family history of breast cancer (n = 5257); family history of bowel cancer (n = 16,464); history of diabetes (n = 313); vitamin D supplement use (n = 564); folate supplement use (n = 564).
FMI fat mass index, TFMI trunk fat mass index, HRT hormone replacement therapy, MET metabolic equivalent, BMI body mass index, IQR interquartile range, WC waist circumference, WHR waist to hip ratio.